Acutus Medical, Inc. (AFIB)
Chart Events
Performance Outlook
| Previous Close | 15.21 |
| Open | 14.94 |
| Bid | 14.90 x 1200 |
| Ask | 15.60 x 1000 |
| Day's Range | 14.86 - 15.62 |
| 52 Week Range | 11.18 - 38.99 |
| Volume | 157,714 |
| Avg. Volume | 350,312 |
| Market Cap | 433.111M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
- GlobeNewswire
Acutus Medical to Announce Second Quarter 2021 Financial Results
CARLSBAD, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today it will release its financial results for the second quarter of 2021 on Thursday, August 12, 2021. In conjunction with the release, Acutus will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent h
- GlobeNewswire
HRS 2021: EP Experts to Demonstrate the Benefits of Acutus Medical’s Complete Suite of EP Technologies
Company’s Innovative Portfolio Aims to Advance Treatment of Atrial & Ventricular ArrhythmiasCARLSBAD, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, will offer a variety of unique clinical and educational opportunities at the 2021 Heart Rhythm Society (HRS) conference happening July 28-31 in Boston, MA. The company and its innovative solutions to
- PR Newswire
AliveCor and Acutus Medical Partner to Evaluate Management and Treatment of Cardiac Arrhythmias
AliveCor, Inc. ("AliveCor"), a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology and services, and Acutus Medical ("Acutus") (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced they will collaborate to assess the integration of data collection tools across the cardiology continuum of care that could potentially advance the field of arrhythmia treatment and disease management.
